d3-Growth hormone receptor polymorphism in acromegaly: effects on metabolic phenotype.
Montefusco L
Clin Endocrinol (Oxf). 72(5):661-7. doi: 10.1111/j.1365-2265.2009.03703.x
Influence of the d3GH receptor polymorphism on the metabolic and biochemical phenotype of GH-deficient adults at baseline and during short- and long-term recombinant human GH replacement therapy.
Giavoli C
Eur J Endocrinol. 2010 Jun 30;163(3):361-8. doi: 10.1530/EJE-10-0317
Filamin A (FLNA) plays an essential role in somatostatin receptor 2 (SST2) signaling and stabilization after agonist stimulation in human and rat somatotroph tumor cells.
Peverelli E
Endocrinology. 2014 May 14;155(8):2932-41. doi: 10.1210/en.2014-1063
Different expression of protein kinase A (PKA) regulatory subunits in normal and neoplastic thyroid tissues.
Ferrero S
Histol Histopathol. 2014 Sep 26;30(4):473-8. doi: 10.14670/HH-30.473
cAMP effects in neuroendocrine tumors: The role of Epac and PKA in cell proliferation and adhesion.
Vitali E
Exp Cell Res. 2015 Nov 14;339(2):241-51. doi: 10.1016/j.yexcr.2015.11.011
Filamin-A is required to mediate SST2 effects in pancreatic neuroendocrine tumours.
Vitali E
Endocr Relat Cancer. 2016 Jan 5;23(3):181-90. doi: 10.1530/ERC-15-0358
Identification of human somatostatin receptor 2 domains involved in internalization and signaling in QGP-1 pancreatic neuroendocrine tumor cell line.
Cambiaghi V
Endocrine. 2016 Jul 12;56(1):146-157. doi: 10.1007/s12020-016-1026-2
Dopamine receptor type 2 (DRD2) inhibits migration and invasion of human tumorous pituitary cells through ROCK-mediated cofilin inactivation.
Peverelli E
Cancer Lett. 2016 Aug 9;381(2):279-86. doi: 10.1016/j.canlet.2016.08.005
Dopamine receptor type 2 (DRD2) and somatostatin receptor type 2 (SSTR2) agonists are effective in inhibiting proliferation of progenitor/stem-like cells isolated from nonfunctioning pituitary tumors.
Peverelli E
Int J Cancer. 2017 Feb 8;140(8):1870-1880. doi: 10.1002/ijc.30613
FLNA is implicated in pulmonary neuroendocrine tumors aggressiveness and progression.
Vitali E
Oncotarget. 2017 Aug 24;8(44):77330-77340. doi: 10.18632/oncotarget.20473